Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Capital Expenditures (2016 - 2026)

Champions Oncology has reported Capital Expenditures over the past 17 years, most recently at $172000.0 for Q1 2026.

  • For Q1 2026, Capital Expenditures rose 26.47% year-over-year to $172000.0; the TTM value through Jan 2026 reached $256000.0, up 88.24%, while the annual FY2025 figure was $197000.0, N/A changed from the prior year.
  • Capital Expenditures for Q1 2026 was $172000.0 at Champions Oncology, up from -$23000.0 in the prior quarter.
  • Over five years, Capital Expenditures peaked at $760000.0 in Q2 2023 and troughed at -$747000.0 in Q1 2024.
  • A 5-year average of $298214.3 and a median of $288500.0 in 2022 define the central range for Capital Expenditures.
  • Biggest five-year swings in Capital Expenditures: tumbled 199.07% in 2024 and later surged 118.21% in 2025.
  • Year by year, Capital Expenditures stood at $604000.0 in 2022, then crashed by 86.92% to $79000.0 in 2023, then plummeted by 1045.57% to -$747000.0 in 2024, then surged by 96.92% to -$23000.0 in 2025, then soared by 847.83% to $172000.0 in 2026.
  • Business Quant data shows Capital Expenditures for CSBR at $172000.0 in Q1 2026, -$23000.0 in Q4 2025, and $46000.0 in Q3 2025.